|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara N: Vascular endothelial growth
factor as a target for anticancer therapy. Oncologist. 9(Suppl 1):
2–10. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rini BI, Halabi S, Rosenberg JE, Stadler
WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher
J, et al: Phase III trial of bevacizumab plus interferon alfa
versus interferon alfa monotherapy in patients with metastatic
renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol.
28:2137–2143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brave SR, Ratcliffe K, Wilson Z, James NH,
Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G,
et al: Assessing the activity of cediranib, a VEGFR-2/3 tyrosine
kinase inhibitor, against VEGFR-1 and members of the structurally
related PDGFR family. Mol Cancer Ther. 10:861–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abdollahi A, Lipson KE, Sckell A, Zieher
H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, et al:
Combined therapy with direct and indirect angiogenesis inhibition
results in enhanced antiangiogenic and antitumor effects. Cancer
Res. 63:8890–8898. 2003.PubMed/NCBI
|
|
8
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cabebe E and Wakelee H: Role of
anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab
and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol.
8:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wedam SB, Low JA, Yang SX, Chow CK, Choyke
P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et
al: Antiangiogenic and antitumor effects of bevacizumab in patients
with inflammatory and locally advanced breast cancer. J Clin Oncol.
24:769–777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morelli MP, Brown AM, Pitts TM, Tentler
JJ, Ciardiello F, Ryan A, Jürgensmeier JM and Eckhardt SG:
Targeting vascular endothelial growth factor receptor-1 and -3 with
cediranib (AZD2171): Effects on migration and invasion of
gastrointestinal cancer cell lines. Mol Cancer Ther. 8:2546–2558.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Molhoek KR, Erdag G, Rasamny JK, Murphy C,
Deacon D, Patterson JW, Slingluff CL Jr and Brautigan DL: VEGFR-2
expression in human melanoma: revised assessment. Int J Cancer.
129:2807–2815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adamcic U, Skowronski K, Peters C,
Morrison J and Coomber BL: The effect of bevacizumab on human
malignant melanoma cells with functional VEGF/VEGFR2 autocrine and
intracrine signaling loops. Neoplasia. 14:612–623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donnem T, Al-Saad S, Al-Shibli K,
Delghandi MP, Persson M, Nilsen MN, Busund LT and Bremnes RM:
Inverse prognostic impact of angiogenic marker expression in tumor
cells versus stromal cells in non small cell lung cancer. Clin
Cancer Res. 13:6649–6657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonnesen B, Pappot H, Holmstav J and Skov
BG: Vascular endothelial growth factor A and vascular endothelial
growth factor receptor 2 expression in non-small cell lung cancer
patients: Relation to prognosis. Lung Cancer. 66:314–318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie
Z, Chen SL, Huang Y, Zhang AY, Yan JF, et al: KDR expression is
associated with the stage and cigarette smoking of the patients
with lung cancer. J Cancer Res Clin Oncol. 133:635–642. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsuyama W, Hashiguchi T, Mizoguchi A,
Iwami F, Kawabata M, Arimura K and Osame M: Serum levels of
vascular endothelial growth factor dependent on the stage
progression of lung cancer. Chest. 118:948–951. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masood R, Cai J, Zheng T, Smith DL, Hinton
DR and Gill PS: Vascular endothelial growth factor (VEGF) is an
autocrine growth factor for VEGF receptor-positive human tumors.
Blood. 98:1904–1913. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bokobza SM, Jiang Y, Weber AM, Devery AM
and Ryan AJ: Short-course treatment with gefitinib enhances
curative potential of radiation therapy in a mouse model of human
non-small cell lung cancer. Int J Radiat Oncol Biol Phys.
88:947–954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pajares MJ, Agorreta J, Larrayoz M, Vesin
A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla
C, et al: Expression of tumor-derived vascular endothelial growth
factor and its receptors is associated with outcome in early
squamous cell carcinoma of the lung. J Clin Oncol. 30:1129–1136.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smith NR, Baker D, James NH, Ratcliffe K,
Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, et al:
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3
are localized primarily to the vasculature in human primary solid
cancers. Clin Cancer Res. 16:3548–3561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holzer TR, Fulford AD, Nedderman DM,
Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman
GD, Schade AE, et al: Tumor cell expression of vascular endothelial
growth factor receptor 2 is an adverse prognostic factor in
patients with squamous cell carcinoma of the lung. PLoS One.
8:e802922013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeng H, Dvorak HF and Mukhopadhyay D:
Vascular permeability factor (VPF)/vascular endothelial growth
factor (VEGF) peceptor-1 down-modulates VPF/VEGF
receptor-2-mediated endothelial cell proliferation, but not
migration, through phos-phatidylinositol 3-kinase-dependent
pathways. J Biol Chem. 276:26969–26979. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Favot L, Keravis T, Holl V, Le Bec A and
Lugnier C: VEGF-induced HUVEC migration and proliferation are
decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 90:334–343.
2003.PubMed/NCBI
|
|
26
|
Prior BM, Yang HT and Terjung RL: What
makes vessels grow with exercise training? J Appl Physiol 1985.
97:1119–1128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumori Y, Yano S, Goto H, Nakataki E,
Wedge SR, Ryan AJ and Sone S: ZD6474, an inhibitor of vascular
endothelial growth factor receptor tyrosine kinase, inhibits growth
of experimental lung metastasis and production of malignant pleural
effusions in a non-small cell lung cancer model. Oncol Res.
16:15–26. 2006.PubMed/NCBI
|
|
28
|
Liang Y, Brekken RA and Hyder SM: Vascular
endothelial growth factor induces proliferation of breast cancer
cells and inhibits the anti-proliferative activity of
anti-hormones. Endocr Relat Cancer. 13:905–919. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanno S, Ohsaki Y, Nakanishi K, Toyoshima
E and Kikuchi K: Human small cell lung cancer cells express
functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer.
46:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu W, Onn A, Isobe T, Itasaka S, Langley
RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al:
Targeted therapy of orthotopic human lung cancer by combined
vascular endothelial growth factor and epidermal growth factor
receptor signaling blockade. Mol Cancer Ther. 6:471–483. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carrillo de Santa Pau E, Arias FC, Caso
Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I,
Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A and del
Val Toledo Lobo M: Prognostic significance of the expression of
vascular endothelial growth factors A, B, C, and D and their
receptors R1, R2, and R3 in patients with nonsmall cell lung
cancer. Cancer. 115:1701–1712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shibuya M: Differential roles of vascular
endothelial growth factor receptor-1 and receptor-2 in
angiogenesis. J Biochem Mol Biol. 39:469–478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brekken RA, Overholser JP, Stastny VA,
Waltenberger J, Minna JD and Thorpe PE: Selective inhibition of
vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1)
activity by a monoclonal anti-VEGF antibody blocks tumor growth in
mice. Cancer Res. 60:5117–5124. 2000.PubMed/NCBI
|
|
34
|
Abid MR, Guo S, Minami T, Spokes KC, Ueki
K, Skurk C, Walsh K and Aird WC: Vascular endothelial growth factor
activates PI3K/Akt/forkhead signaling in endothelial cells.
Arterioscler Thromb Vasc Biol. 24:294–300. 2004. View Article : Google Scholar
|
|
35
|
Silva SR, Bowen KA, Rychahou PG, Jackson
LN, Weiss HL, Lee EY, Townsend CM Jr and Evers BM: VEGFR-2
expression in carcinoid cancer cells and its role in tumor growth
and metastasis. Int J Cancer. 128:1045–1056. 2011. View Article : Google Scholar
|
|
36
|
Adham SA, Sher I and Coomber BL: Molecular
blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab
Invest. 90:709–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dias S, Hattori K, Zhu Z, Heissig B, Choy
M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, et al: Autocrine
stimulation of VEGFR-2 activates human leukemic cell growth and
migration. J Clin Invest. 106:511–521. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blumenschein GR Jr, Gatzemeier U, Fossella
F, Stewart DJ, Cupit L, Cihon F, O'Leary J and Reck M: Phase II,
multicenter, uncontrolled trial of single-agent sorafenib in
patients with relapsed or refractory, advanced non-small-cell lung
cancer. J Clin Oncol. 27:4274–4280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Socinski MA, Novello S, Brahmer JR, Rosell
R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH,
Pallares C, et al: Multicenter, phase II trial of sunitinib in
previously treated, advanced non-small-cell lung cancer. J Clin
Oncol. 26:650–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schiller JH, Larson T, Ou SH, Limentani S,
Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, et al:
Efficacy and safety of axitinib in patients with advanced
non-small-cell lung cancer: Results from a phase II study. J Clin
Oncol. 27:3836–3841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chatterjee S, Heukamp LC, Siobal M,
Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K,
Meder L, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop
triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740.
2013. View Article : Google Scholar : PubMed/NCBI
|
